The WHO BPaLM Accelerator Platform was established in January 2023, right after the update of WHO guidelines on the treatment of drug-resistant TB in 2022. The purpose of the WHO BPaLM Accelerator Platform is to support countries and stakeholders in information exchange and technical discussions to address challenges in the adoption and implementation of the BPaLM/BPaL regimen. This is also to support the Call to Action on rolling out of the BPaLM regimen and other short regimens for treatment of TB that was initiated by WHO and its multiple partners.
Since January 2025, the platform has been rebranded to WHO Accelerator Platform for Novel TB regimens in order to broader its scope in supporting scale up of different novel TB regimens.
The platform participants include broad representation from national TB programmes of high TB burden countries from all regions, civil society, technical and funding partners involved in the implementation of the novel TB regimen and supporting TB care.
The WHO Accelerator Platform for Novel TB regimens virtual meetings are organized monthly or bi-monthly, covering topics around implementation aspects of the shorter, more effective and safer regimens. The topics presented and discussed are suggested to benefit the platform participants and they usually are focusing on country experience sharing, implementation challenges and practical solutions, and frequently asked questions and answers. Presentations or interactive discussions are typically delivered by technical partners, civil society, or country representatives.
If you want to join the platform, please fill the subscription form and email it to bpalmplatform@who.int.
- Presentations and notes for record of the WHO BPaLM Accelerator Platform meetings.
- CALL TO ACTION: Shorter and more effective treatment for all people suffering from drug-resistant TB
- Sign-up for Call to Action
- WHO consolidated guidelines on tuberculosis: module 4: treatment and care
- WHO consolidated operational handbook on tuberculosis: module 4: treatment and care
- Customized cost effectiveness analysis for implementing six-month drug-resistant TB treatments SLASH-TB